Global Pain Management Drugs Market
Description
Pain Management Drugs Market Size and Trends
The global pain management drugs market was valued as US$ 63.79 billion in 2024 and is expected to reach US$ 122.29 billion by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033, according to DataM Intelligence report.
The market is driven by the rising prevalence of chronic pain conditions such as chronic low back pain, arthritis, neuropathic pain, chronic migraine and headache disorders, the growing geriatric population, and the development of novel drugs. As people age, pain conditions increase, boosting dependency on pain management drugs. Pharmaceutical companies are focusing on innovative therapies, including non-opioid alternatives and nanoparticle-based drugs, for better efficacy and fewer side effects. These developments address unmet needs, especially concerns over long-term opioid use. North America holds a dominant share, supported by well-developed healthcare infrastructure, high prescription rates, and strong presence of market players offering branded medications. The U.S. contributes significantly, with rising chronic diseases and easy access to top-selling branded drugs.
Key Highlights from the Report
• North America leads the pain management drugs market, valued at US$ 25.85 billion in 2024, driven by well-developed healthcare, high prescription rates, and major players like Pfizer and Teva Pharmaceuticals offering branded medications.
• Asia-Pacific is the fastest-growing region, projected at a CAGR of 9.2%, with rising chronic pain prevalence in countries like China, Japan, and India, and new approvals like VIVOZON’s UNAFRA Inj. in South Korea.
• Non-steroidal anti-inflammatory drugs (NSAIDs) remain the leading drug type, valued at US$ 38.48 billion in 2024, supported by wide use for conditions like arthritis and migraines, and innovations in formulations.
• Arthritis pain is a key indication segment, valued at US$ 14.53 billion in 2024, as it affects over 350 million people globally and drives demand for NSAIDs and other relievers.
• The market is competitive, with players like Bayer AG, Haleon, Kenvue, Teva Pharmaceuticals, and Pfizer focusing on new launches, approvals, and formulations to address opioid concerns and expand options.
Market Dynamics
Drivers - Rising Prevalence of Chronic Pain Conditions and Development of Novel Drugs
The pain management drugs market is growing due to the increasing prevalence of chronic pain conditions like osteoarthritis, back pain, neuropathic pain, fibromyalgia, and cancer-related pain. The aging population contributes to this rise, boosting demand for these drugs. For instance, a global disease burden study on arthritis published in The Lancet Rheumatology stated that in 2020, approximately 595 million people suffered from osteoarthritis, with knee cases expected to increase by 78.6%, hand by 48.6%, hip by 74.9%, and other types by 95.1% by 2050. Cancer incidence is also rising, with the International Agency for Research on Cancer projecting nearly 24 million cases in 2030 and 30 million in 2040, increasing the need for pain relief in affected patients. This surge in chronic conditions creates strong demand, propelling market growth.
The market is also driven by the development of novel drugs, as pharmaceutical companies advance research for more effective treatments. For instance, in February 2024, Hikma Pharmaceuticals launched COMBOGESIC IV, an opioid-free injection combining acetaminophen and ibuprofen for mild to moderate pain relief and as an adjunct to opioids for severe pain. In February 2023, Anglo-French Drugs & Industries launched AFD-NP, combining Nortriptyline and Pregabalin for moderate to severe neuropathic pain, approved by the Drug Control Department. These innovations offer better efficacy, fewer side effects, and broader applications, expanding the market.
Restraints: Side Effects Associated with the Drugs
The pain management drugs market faces restraints from side effects, especially with prolonged use of opioids and NSAIDs. Opioids have abuse potential, leading to addiction, respiratory depression, gastrointestinal issues, and cardiovascular events. NSAIDs, while safer short-term, can cause upper gastrointestinal discomfort in 13-15% of users, exacerbate 25% of peptic ulcer cases, and increase cardiovascular risk by 25%, per a study in Nature Scientific Reports in March 2024. These effects are minimal in acute use but threaten chronic users, potentially decreasing adoption of traditional drugs.
Although, Competition from non-pharmacological alternatives hinders market growth, as patients shift toward drug-free options amid health awareness. Alternatives gaining traction include acupuncture, hypnosis, massage, mindfulness meditation, music-based interventions, spinal manipulation, tai chi, qigong, yoga, chiropractic therapies, therapeutic touch, herbal therapies, and dietary approaches. This preference for safer, non-addictive methods limits demand for traditional drugs, requiring companies to innovate to stay competitive.
Opportunities - Market Expansion for Pain Management Drugs in Low-income Countries
The market has opportunities in expanding to low-income countries, where access to palliative care and pain relief is limited. A 2023 WHO report highlighted unequal morphine distribution, a key ingredient for pain drugs, failing to meet needs in many regions. A 2019 National Institute of Health report noted that while 298 metric tons of morphine-equivalent opioids are distributed worldwide annually, only 0.03% reaches low-income countries, where over 80% of pain sufferers live with limited or no palliative care. Developing affordable solutions for these areas can open new markets, support business growth, and improve global healthcare.
Segmentation Analysis
By Drug Type - Non-Steroidal Anti-Inflammatory Drugs Segment Leads the Market
The non-steroidal anti-inflammatory drugs (NSAIDs) segment was valued at US$ 38.48 billion in 2024 and is estimated to reach US$ 83.63 billion by 2033, growing at a CAGR of 9.1% during the forecast period (2025-2033). NSAIDs are widely used for mild to moderate pain and inflammation, including medications like acetaminophen, aspirin, ibuprofen, naproxen, diclofenac, and celecoxib. They manage pain from musculoskeletal conditions, arthritis, post-surgical recovery, and migraines. Musculoskeletal issues affect over 1.7 billion people globally, per the George Institute for Global Health, with chronic pain impacting 20-30% and lower back pain a growing burden. Arthritis affects 350 million, lower back pain over 540 million, post-surgical pain follows 234 million annual surgeries, menstrual cramps 80% of women, and migraines 1 in 7 people. Major companies include Pfizer (Celebrex), Bayer (Aspirin), Kenvue (Tylenol), and Haleon (Voltaren Gel). Innovations focus on topical, extended-release, and combination therapies to reduce gastrointestinal side effects and improve safety.
The opioids drug type segment was valued at US$ 17.32 billion in 2024 and is estimated to reach US$ 25.67 billion by 2033, growing at a CAGR of 4.5% during the forecast period (2025-2033). Opioids are effective for severe pain like cancer-related, post-surgical, and neuropathic, including oxycodone, hydrocodone, codeine, morphine, and fentanyl. However, addiction is a challenge, with over 100,000 annual overdose deaths per the CDC. Regulatory controls from the FDA and DEA push for alternatives. Companies like Purdue Pharma, Teva Pharmaceuticals, Mallinckrodt, Pfizer, and Collegium focus on abuse-deterrent and extended-release formulations. Opioids address surgical pain (40-50% of post-operative patients), severe trauma, chronic diffuse pain (10-15% of adults), and end-of-life care. The industry shifts toward safer options to balance relief and reduce addiction risks.
By Indication - Arthritis Pain Segment Dominates with Strong Market Expansion
The arthritis pain segment was valued at US$ 14.53 billion in 2024 and is estimated to reach US$ 31.43 billion by 2033, growing at a CAGR of 9.0% during the forecast period (2025-2033). Arthritis pain management drugs reduce inflammation, relieve pain, and improve joint function by targeting pathways or suppressing immune responses. Arthritis affects over 350 million globally and causes 25% of years lived with disability, per the WHO. Lifestyle factors like obesity and sedentary habits increase cases. Over-the-counter relievers like ibuprofen and acetaminophen are popular, with opioids for severe cases and CBD products gaining traction. Research drives growth; in February 2025, the Institute of Nano Science and Technology developed a self-actuating system using microspheres with methotrexate, releasing medication at inflamed joints via enzymes for targeted, safer treatment.
The back pain segment was valued at US$ 12.21 billion in 2024 and is estimated to reach US$ 26.83 billion by 2033, growing at a CAGR of 9.2% during the forecast period (2025-2033). Back pain management drugs alleviate acute and chronic pain from sedentary lifestyles, aging, and work-related disorders. Low back pain affected 619 million globally in 2020, rising to 843 million by 2050 per the WHO, driven by population growth and aging. NSAIDs are most prescribed, with opioids, muscle relaxants, and corticosteroids for severe cases. Innovations include a March 2025 German development of VER-01, a cannabis-based painkiller showing reduced pain and improved sleep in a trial of 800 chronic lower back pain patients, offering a non-addictive opioid alternative.
By Mode of Prescription - Prescription Pain Drugs See Strong Demand Amid Aging Population and Rising Chronic Conditions
The prescription-based segment was valued at US$ 38.36 billion in 2024 and is estimated to reach US$ 70.61 billion by 2033, growing at a CAGR of 7.1% during the forecast period (2025-2033). Prescription-based drugs require doctor authorization for moderate to severe pain, including opioids, NSAIDs, muscle relaxants, antidepressants, and anticonvulsants. They alter pain signals to reduce discomfort. Growth comes from effectiveness in post-surgical, chronic, and cancer pain, plus aging populations and drug advancements. By 2030, one in six people will be 60 or older, rising from 1 billion in 2020 to 1.4 billion, and doubling to 2.1 billion by 2050 per the WHO, increasing chronic pain like arthritis and osteoporosis.
The over-the-counter (OTC) segment was valued at US$ 25.43 billion in 2024 and is estimated to reach US$ 51.67 billion by 2033, growing at a CAGR of 8.3% during the forecast period (2025-2033). OTC drugs relieve mild to moderate pain, inflammation, and fever without prescription, for headaches, muscle pain, arthritis, and more, including acetaminophen, ibuprofen, and aspirin. Accessibility, affordability, and trust drive share, with self-medication and chronic pain prevalence. Approvals boost growth; in July 2023, Granules India got USFDA approval for Acetaminophen and Ibuprofen Tablets, equivalent to Advil Dual Action, for headaches, aches, cramps, and arthritis. In April 2022, Genexa launched preservative-free acetaminophen relievers, shifting toward natural options.
Regional Insights
North America Pain Management Drugs Market Trends
The pain management drugs market in North America was valued at US$ 25.85 billion in 2024 and is estimated to reach US$ 46.87 billion by 2033, growing at a CAGR of 6.9% during the forecast period (2025-2033). North America dominates, especially the U.S. and Canada, due to chronic disease prevalence, advanced healthcare, strong market players, branded drug access, and high prescriptions. A January 2023 study in the Journal of International Medical Research noted 5.3 million adults use prescription opioids frequently for chronic pain.
The CDC reported 150 million opioid prescriptions in 2023. A March 2024 Anesthesiology Journal study showed increased prescriptions of NSAIDs, acetaminophen, opioids, neuropathic agents, and muscle relaxants up to 2022. High drug prices contribute; in 2022, U.S. prices were 2.78 times higher than other nations per the U.S. Department of Health and Human Services. Approvals drive growth; in January 2025, the FDA approved Vertex’s JOURNAVX (suzetrigine), a non-opioid for moderate-to-severe acute pain.
Europe Pain Management Drugs Market Trends
The pain management drugs market in Europe was valued at US$ 17.13 billion in 2024 and is estimated to reach US$ 33.77 billion by 2033, growing at a CAGR of 7.9% during the forecast period (2025-2033).
Rising chronic pain from aging drives growth, affecting 150 million or one in five adults per November 2024 European Commission data, impacting quality of life. Countries like Germany, France, Italy, and the UK lead due to chronic pain burden. The 2024 European Pain Federation’s European Pain Awareness Day raises awareness, reduces stigma, and advocates for better treatments. Governments focus on cost-effective generics and affordable strategies. Innovations include the 2024 launch of Panadol Dual Action (paracetamol and ibuprofen) in Central and Eastern Europe for enhanced relief. Clinical trials advance; in February 2025, Algiax Pharmaceuticals reported positive Phase 2a data for AP-325, an allosteric GABAA-receptor modulator for chronic neuropathic pain, in trials across Germany, Spain, Czech Republic, Belgium, and France.
Asia-Pacific Pain Management Drugs Market Trends
The pain management drugs market in Asia-Pacific was valued at US$ 14.23 billion in 2024 and is estimated to reach US$ 31.30 billion by 2033, growing at a CAGR of 9.2% during the forecast period (2025-2033).
High low back pain prevalence drives demand; a 2022 Indian Journal of Anaesthesia study showed 66% lifetime prevalence in Indians, a common musculoskeletal issue. Chronic conditions like arthritis, musculoskeletal disorders, and neuropathic pain rise in China, Japan, and India. Approvals propel growth; in February 2025, VIVOZON’s UNAFRA Inj., a non-opioid, non-NSAID analgesic with opiranserin HCl, got South Korea’s MFDS approval for rapid, addiction-free relief. In September 2024, Mankind Pharma launched Nimulid Strong, a 2X diclofenac gel and spray for enhanced pain relief.
Latin America Pain Management Drugs Market Trends
The pain management drugs market in Latin America was valued at US$ 4.07 billion in 2024 and is estimated to reach US$ 6.58 billion by 2033, growing at a CAGR of 5.6% during the forecast period (2025-2033).
Rising chronic pain, aging, and healthcare awareness drive growth; May 2023 Elsevier Clinics data showed chronic pain affects 35-47% of adults and older adults. Musculoskeletal disorders, arthritis, and neuropathic pain are common in Mexico and Argentina, boosting demand for NSAIDs, opioids, and alternatives. Partnerships advance; in January 2025, SteinCares partnered with Molteni Farmaceutici to expand Oramorph (morphine oral solution) availability. In July 2024, Hyloris Pharmaceuticals agreed with Halex Istar to introduce Maxigesic IV, a non-opioid intravenous treatment, in Brazil, South America’s largest pharmaceutical market.
Middle East and Africa Pain Management Drugs Market Trends
The Middle East and Africa pain management drugs market was valued at US$ 2.50 billion in 2024 and is estimated to reach US$ 3.76 billion by 2033, growing at a CAGR of 4.7% during the forecast period (2025-2033).
High chronic pain from arthritis, musculoskeletal disorders, and cancer, plus aging, drives growth. Back and neuropathic pain increase demand. Healthcare initiatives like the Haleon Pain Management Institute raise awareness and educate professionals. Governments improve systems and access. In January 2025 at DUPHAT, Haleon launched the Haleon Pain Management Institute to empower professionals with research, resources, and training for better outcomes.
Competitive Landscape:
The following are the major companies operating in the pain management drugs market. These players hold a significant share and play an important role in shaping market growth and trends.
• Bayer AG
• Haleon Group of Companies
• Kenvue
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc
• Pfizer Inc.
• Purdue Pharmaceuticals L.P.
• Abbott
• Collegium Pharmaceutical, Inc.
• Sun Pharmaceutical Industries Ltd
The pain management drugs market is competitive, with major players like Bayer AG, Haleon, Kenvue, Teva Pharmaceuticals, and Pfizer focusing on new launches, approvals, and formulations. Companies emphasize non-opioid options, abuse-deterrent products, and innovations to address addiction risks and expand therapies.
Latest Developments and Breakthroughs
1. In February 2023 - Anglo-French Drugs & Industries Ltd. has announced the launch of a new product, AFD-NP, designed for the treatment of moderate to severe neuropathic pain. This innovative product combines Nortriptyline and Pregabalin. AFD-NP has received approval from the Drug Control Department, marking a significant step forward in addressing the needs of patients suffering from neuropathic pain.
2. In February 2024 - Hikma Pharmaceuticals PLC, launched COMBOGESIC IV (acetaminophen and ibuprofen) injection in the United States. COMBOGESIC IV is an opioid-free intravenous pain relief treatment, combining 1,000 mg of acetaminophen with 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) for relief of mild to moderate pain, and management of moderate to severe pain as an adjunct to opioid analgesics.
3. In January 2025 - Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX (suzetrigine), an oral, non-opioid pain relief medication. JOURNAVX is a highly selective NaV1.8 pain signal inhibitor designed for the treatment of adults with moderate-to-severe acute pain. This effective and well-tolerated medicine is free from evidence of addictive potential and is approved for use in managing various types of moderate-to-severe acute pain.
The global pain management drugs market was valued as US$ 63.79 billion in 2024 and is expected to reach US$ 122.29 billion by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033, according to DataM Intelligence report.
The market is driven by the rising prevalence of chronic pain conditions such as chronic low back pain, arthritis, neuropathic pain, chronic migraine and headache disorders, the growing geriatric population, and the development of novel drugs. As people age, pain conditions increase, boosting dependency on pain management drugs. Pharmaceutical companies are focusing on innovative therapies, including non-opioid alternatives and nanoparticle-based drugs, for better efficacy and fewer side effects. These developments address unmet needs, especially concerns over long-term opioid use. North America holds a dominant share, supported by well-developed healthcare infrastructure, high prescription rates, and strong presence of market players offering branded medications. The U.S. contributes significantly, with rising chronic diseases and easy access to top-selling branded drugs.
Key Highlights from the Report
• North America leads the pain management drugs market, valued at US$ 25.85 billion in 2024, driven by well-developed healthcare, high prescription rates, and major players like Pfizer and Teva Pharmaceuticals offering branded medications.
• Asia-Pacific is the fastest-growing region, projected at a CAGR of 9.2%, with rising chronic pain prevalence in countries like China, Japan, and India, and new approvals like VIVOZON’s UNAFRA Inj. in South Korea.
• Non-steroidal anti-inflammatory drugs (NSAIDs) remain the leading drug type, valued at US$ 38.48 billion in 2024, supported by wide use for conditions like arthritis and migraines, and innovations in formulations.
• Arthritis pain is a key indication segment, valued at US$ 14.53 billion in 2024, as it affects over 350 million people globally and drives demand for NSAIDs and other relievers.
• The market is competitive, with players like Bayer AG, Haleon, Kenvue, Teva Pharmaceuticals, and Pfizer focusing on new launches, approvals, and formulations to address opioid concerns and expand options.
Market Dynamics
Drivers - Rising Prevalence of Chronic Pain Conditions and Development of Novel Drugs
The pain management drugs market is growing due to the increasing prevalence of chronic pain conditions like osteoarthritis, back pain, neuropathic pain, fibromyalgia, and cancer-related pain. The aging population contributes to this rise, boosting demand for these drugs. For instance, a global disease burden study on arthritis published in The Lancet Rheumatology stated that in 2020, approximately 595 million people suffered from osteoarthritis, with knee cases expected to increase by 78.6%, hand by 48.6%, hip by 74.9%, and other types by 95.1% by 2050. Cancer incidence is also rising, with the International Agency for Research on Cancer projecting nearly 24 million cases in 2030 and 30 million in 2040, increasing the need for pain relief in affected patients. This surge in chronic conditions creates strong demand, propelling market growth.
The market is also driven by the development of novel drugs, as pharmaceutical companies advance research for more effective treatments. For instance, in February 2024, Hikma Pharmaceuticals launched COMBOGESIC IV, an opioid-free injection combining acetaminophen and ibuprofen for mild to moderate pain relief and as an adjunct to opioids for severe pain. In February 2023, Anglo-French Drugs & Industries launched AFD-NP, combining Nortriptyline and Pregabalin for moderate to severe neuropathic pain, approved by the Drug Control Department. These innovations offer better efficacy, fewer side effects, and broader applications, expanding the market.
Restraints: Side Effects Associated with the Drugs
The pain management drugs market faces restraints from side effects, especially with prolonged use of opioids and NSAIDs. Opioids have abuse potential, leading to addiction, respiratory depression, gastrointestinal issues, and cardiovascular events. NSAIDs, while safer short-term, can cause upper gastrointestinal discomfort in 13-15% of users, exacerbate 25% of peptic ulcer cases, and increase cardiovascular risk by 25%, per a study in Nature Scientific Reports in March 2024. These effects are minimal in acute use but threaten chronic users, potentially decreasing adoption of traditional drugs.
Although, Competition from non-pharmacological alternatives hinders market growth, as patients shift toward drug-free options amid health awareness. Alternatives gaining traction include acupuncture, hypnosis, massage, mindfulness meditation, music-based interventions, spinal manipulation, tai chi, qigong, yoga, chiropractic therapies, therapeutic touch, herbal therapies, and dietary approaches. This preference for safer, non-addictive methods limits demand for traditional drugs, requiring companies to innovate to stay competitive.
Opportunities - Market Expansion for Pain Management Drugs in Low-income Countries
The market has opportunities in expanding to low-income countries, where access to palliative care and pain relief is limited. A 2023 WHO report highlighted unequal morphine distribution, a key ingredient for pain drugs, failing to meet needs in many regions. A 2019 National Institute of Health report noted that while 298 metric tons of morphine-equivalent opioids are distributed worldwide annually, only 0.03% reaches low-income countries, where over 80% of pain sufferers live with limited or no palliative care. Developing affordable solutions for these areas can open new markets, support business growth, and improve global healthcare.
Segmentation Analysis
By Drug Type - Non-Steroidal Anti-Inflammatory Drugs Segment Leads the Market
The non-steroidal anti-inflammatory drugs (NSAIDs) segment was valued at US$ 38.48 billion in 2024 and is estimated to reach US$ 83.63 billion by 2033, growing at a CAGR of 9.1% during the forecast period (2025-2033). NSAIDs are widely used for mild to moderate pain and inflammation, including medications like acetaminophen, aspirin, ibuprofen, naproxen, diclofenac, and celecoxib. They manage pain from musculoskeletal conditions, arthritis, post-surgical recovery, and migraines. Musculoskeletal issues affect over 1.7 billion people globally, per the George Institute for Global Health, with chronic pain impacting 20-30% and lower back pain a growing burden. Arthritis affects 350 million, lower back pain over 540 million, post-surgical pain follows 234 million annual surgeries, menstrual cramps 80% of women, and migraines 1 in 7 people. Major companies include Pfizer (Celebrex), Bayer (Aspirin), Kenvue (Tylenol), and Haleon (Voltaren Gel). Innovations focus on topical, extended-release, and combination therapies to reduce gastrointestinal side effects and improve safety.
The opioids drug type segment was valued at US$ 17.32 billion in 2024 and is estimated to reach US$ 25.67 billion by 2033, growing at a CAGR of 4.5% during the forecast period (2025-2033). Opioids are effective for severe pain like cancer-related, post-surgical, and neuropathic, including oxycodone, hydrocodone, codeine, morphine, and fentanyl. However, addiction is a challenge, with over 100,000 annual overdose deaths per the CDC. Regulatory controls from the FDA and DEA push for alternatives. Companies like Purdue Pharma, Teva Pharmaceuticals, Mallinckrodt, Pfizer, and Collegium focus on abuse-deterrent and extended-release formulations. Opioids address surgical pain (40-50% of post-operative patients), severe trauma, chronic diffuse pain (10-15% of adults), and end-of-life care. The industry shifts toward safer options to balance relief and reduce addiction risks.
By Indication - Arthritis Pain Segment Dominates with Strong Market Expansion
The arthritis pain segment was valued at US$ 14.53 billion in 2024 and is estimated to reach US$ 31.43 billion by 2033, growing at a CAGR of 9.0% during the forecast period (2025-2033). Arthritis pain management drugs reduce inflammation, relieve pain, and improve joint function by targeting pathways or suppressing immune responses. Arthritis affects over 350 million globally and causes 25% of years lived with disability, per the WHO. Lifestyle factors like obesity and sedentary habits increase cases. Over-the-counter relievers like ibuprofen and acetaminophen are popular, with opioids for severe cases and CBD products gaining traction. Research drives growth; in February 2025, the Institute of Nano Science and Technology developed a self-actuating system using microspheres with methotrexate, releasing medication at inflamed joints via enzymes for targeted, safer treatment.
The back pain segment was valued at US$ 12.21 billion in 2024 and is estimated to reach US$ 26.83 billion by 2033, growing at a CAGR of 9.2% during the forecast period (2025-2033). Back pain management drugs alleviate acute and chronic pain from sedentary lifestyles, aging, and work-related disorders. Low back pain affected 619 million globally in 2020, rising to 843 million by 2050 per the WHO, driven by population growth and aging. NSAIDs are most prescribed, with opioids, muscle relaxants, and corticosteroids for severe cases. Innovations include a March 2025 German development of VER-01, a cannabis-based painkiller showing reduced pain and improved sleep in a trial of 800 chronic lower back pain patients, offering a non-addictive opioid alternative.
By Mode of Prescription - Prescription Pain Drugs See Strong Demand Amid Aging Population and Rising Chronic Conditions
The prescription-based segment was valued at US$ 38.36 billion in 2024 and is estimated to reach US$ 70.61 billion by 2033, growing at a CAGR of 7.1% during the forecast period (2025-2033). Prescription-based drugs require doctor authorization for moderate to severe pain, including opioids, NSAIDs, muscle relaxants, antidepressants, and anticonvulsants. They alter pain signals to reduce discomfort. Growth comes from effectiveness in post-surgical, chronic, and cancer pain, plus aging populations and drug advancements. By 2030, one in six people will be 60 or older, rising from 1 billion in 2020 to 1.4 billion, and doubling to 2.1 billion by 2050 per the WHO, increasing chronic pain like arthritis and osteoporosis.
The over-the-counter (OTC) segment was valued at US$ 25.43 billion in 2024 and is estimated to reach US$ 51.67 billion by 2033, growing at a CAGR of 8.3% during the forecast period (2025-2033). OTC drugs relieve mild to moderate pain, inflammation, and fever without prescription, for headaches, muscle pain, arthritis, and more, including acetaminophen, ibuprofen, and aspirin. Accessibility, affordability, and trust drive share, with self-medication and chronic pain prevalence. Approvals boost growth; in July 2023, Granules India got USFDA approval for Acetaminophen and Ibuprofen Tablets, equivalent to Advil Dual Action, for headaches, aches, cramps, and arthritis. In April 2022, Genexa launched preservative-free acetaminophen relievers, shifting toward natural options.
Regional Insights
North America Pain Management Drugs Market Trends
The pain management drugs market in North America was valued at US$ 25.85 billion in 2024 and is estimated to reach US$ 46.87 billion by 2033, growing at a CAGR of 6.9% during the forecast period (2025-2033). North America dominates, especially the U.S. and Canada, due to chronic disease prevalence, advanced healthcare, strong market players, branded drug access, and high prescriptions. A January 2023 study in the Journal of International Medical Research noted 5.3 million adults use prescription opioids frequently for chronic pain.
The CDC reported 150 million opioid prescriptions in 2023. A March 2024 Anesthesiology Journal study showed increased prescriptions of NSAIDs, acetaminophen, opioids, neuropathic agents, and muscle relaxants up to 2022. High drug prices contribute; in 2022, U.S. prices were 2.78 times higher than other nations per the U.S. Department of Health and Human Services. Approvals drive growth; in January 2025, the FDA approved Vertex’s JOURNAVX (suzetrigine), a non-opioid for moderate-to-severe acute pain.
Europe Pain Management Drugs Market Trends
The pain management drugs market in Europe was valued at US$ 17.13 billion in 2024 and is estimated to reach US$ 33.77 billion by 2033, growing at a CAGR of 7.9% during the forecast period (2025-2033).
Rising chronic pain from aging drives growth, affecting 150 million or one in five adults per November 2024 European Commission data, impacting quality of life. Countries like Germany, France, Italy, and the UK lead due to chronic pain burden. The 2024 European Pain Federation’s European Pain Awareness Day raises awareness, reduces stigma, and advocates for better treatments. Governments focus on cost-effective generics and affordable strategies. Innovations include the 2024 launch of Panadol Dual Action (paracetamol and ibuprofen) in Central and Eastern Europe for enhanced relief. Clinical trials advance; in February 2025, Algiax Pharmaceuticals reported positive Phase 2a data for AP-325, an allosteric GABAA-receptor modulator for chronic neuropathic pain, in trials across Germany, Spain, Czech Republic, Belgium, and France.
Asia-Pacific Pain Management Drugs Market Trends
The pain management drugs market in Asia-Pacific was valued at US$ 14.23 billion in 2024 and is estimated to reach US$ 31.30 billion by 2033, growing at a CAGR of 9.2% during the forecast period (2025-2033).
High low back pain prevalence drives demand; a 2022 Indian Journal of Anaesthesia study showed 66% lifetime prevalence in Indians, a common musculoskeletal issue. Chronic conditions like arthritis, musculoskeletal disorders, and neuropathic pain rise in China, Japan, and India. Approvals propel growth; in February 2025, VIVOZON’s UNAFRA Inj., a non-opioid, non-NSAID analgesic with opiranserin HCl, got South Korea’s MFDS approval for rapid, addiction-free relief. In September 2024, Mankind Pharma launched Nimulid Strong, a 2X diclofenac gel and spray for enhanced pain relief.
Latin America Pain Management Drugs Market Trends
The pain management drugs market in Latin America was valued at US$ 4.07 billion in 2024 and is estimated to reach US$ 6.58 billion by 2033, growing at a CAGR of 5.6% during the forecast period (2025-2033).
Rising chronic pain, aging, and healthcare awareness drive growth; May 2023 Elsevier Clinics data showed chronic pain affects 35-47% of adults and older adults. Musculoskeletal disorders, arthritis, and neuropathic pain are common in Mexico and Argentina, boosting demand for NSAIDs, opioids, and alternatives. Partnerships advance; in January 2025, SteinCares partnered with Molteni Farmaceutici to expand Oramorph (morphine oral solution) availability. In July 2024, Hyloris Pharmaceuticals agreed with Halex Istar to introduce Maxigesic IV, a non-opioid intravenous treatment, in Brazil, South America’s largest pharmaceutical market.
Middle East and Africa Pain Management Drugs Market Trends
The Middle East and Africa pain management drugs market was valued at US$ 2.50 billion in 2024 and is estimated to reach US$ 3.76 billion by 2033, growing at a CAGR of 4.7% during the forecast period (2025-2033).
High chronic pain from arthritis, musculoskeletal disorders, and cancer, plus aging, drives growth. Back and neuropathic pain increase demand. Healthcare initiatives like the Haleon Pain Management Institute raise awareness and educate professionals. Governments improve systems and access. In January 2025 at DUPHAT, Haleon launched the Haleon Pain Management Institute to empower professionals with research, resources, and training for better outcomes.
Competitive Landscape:
The following are the major companies operating in the pain management drugs market. These players hold a significant share and play an important role in shaping market growth and trends.
• Bayer AG
• Haleon Group of Companies
• Kenvue
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc
• Pfizer Inc.
• Purdue Pharmaceuticals L.P.
• Abbott
• Collegium Pharmaceutical, Inc.
• Sun Pharmaceutical Industries Ltd
The pain management drugs market is competitive, with major players like Bayer AG, Haleon, Kenvue, Teva Pharmaceuticals, and Pfizer focusing on new launches, approvals, and formulations. Companies emphasize non-opioid options, abuse-deterrent products, and innovations to address addiction risks and expand therapies.
Latest Developments and Breakthroughs
1. In February 2023 - Anglo-French Drugs & Industries Ltd. has announced the launch of a new product, AFD-NP, designed for the treatment of moderate to severe neuropathic pain. This innovative product combines Nortriptyline and Pregabalin. AFD-NP has received approval from the Drug Control Department, marking a significant step forward in addressing the needs of patients suffering from neuropathic pain.
2. In February 2024 - Hikma Pharmaceuticals PLC, launched COMBOGESIC IV (acetaminophen and ibuprofen) injection in the United States. COMBOGESIC IV is an opioid-free intravenous pain relief treatment, combining 1,000 mg of acetaminophen with 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) for relief of mild to moderate pain, and management of moderate to severe pain as an adjunct to opioid analgesics.
3. In January 2025 - Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX (suzetrigine), an oral, non-opioid pain relief medication. JOURNAVX is a highly selective NaV1.8 pain signal inhibitor designed for the treatment of adults with moderate-to-severe acute pain. This effective and well-tolerated medicine is free from evidence of addictive potential and is approved for use in managing various types of moderate-to-severe acute pain.
Table of Contents
234 Pages
- 1. Market Introduction and Scope
- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope
- 2. Executive Insights and Key Takeaways
- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Drug Type
- 2.4. Snippet by Indication
- 2.5. Snippet by Mode of Prescription
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region
- 3. Dynamics
- 3.1. Impacting Factors
- 3.1.1. Drivers
- 3.1.1.1. Rising Prevalence of Chronic Pain Conditions
- 3.1.1.2. Rising Development of Novel Drugs
- 3.1.1.3. XX
- 3.1.2. Restraints
- 3.1.2.1. Side Effects Associated with the Drugs
- 3.1.2.2. Competition from Alternative Pain Management Treatments
- 3.1.2.3. XX
- 3.1.3. Opportunity
- 3.1.3.1. Market Expansion for Pain Management Drugs in Low-income Countries
- 3.1.3.2. XX
- 3.1.4. Impact Analysis
- 4. Strategic Insights and Industry Outlook
- 4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established leaders with largest selling Brand
- 4.1.3. Market leaders with established Product
- 4.2. CXO Perspectives
- 4.3. Latest Developments and Breakthroughs
- 4.4. Case Studies/Ongoing Research
- 4.5. Regulatory and Reimbursement Landscape
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. Asia Pacific
- 4.5.4. Latin America
- 4.5.5. Middle East & Africa
- 4.6. Porter’s Five Force Analysis
- 4.7. Supply Chain Analysis
- 4.8. Patent Analysis
- 4.9. SWOT Analysis
- 4.10. Unmet Needs and Gaps
- 4.11. Recommended Strategies for Market Entry and Expansion
- 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.13. Pricing Analysis and Price Dynamics
- 4.14. Key Opinion Leaders
- 5. By Drug Type
- 5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 5.1.2. Market Attractiveness Index, By Drug Type
- 5.2. Non-Steroidal Anti-Inflammatory Drugs*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Opioids
- 5.4. Corticosteroids
- 5.5. Muscle Relaxants
- 5.6. Anticonvulsant Drugs
- 5.7. Others
- 6. By Indication
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 6.1.2. Market Attractiveness Index, By Indication
- 6.2. Arthritis Pain*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Back Pain
- 6.4. Surgery Pain
- 6.5. Headaches & Migraine
- 6.6. Injury Pain
- 6.7. Cancer Pain
- 6.8. Fibromyalgia
- 6.9. Muscle Spasms
- 6.10. Menstrual Pain
- 6.11. Neuropathic Pain
- 6.12. Others
- 7. By Mode of Prescription
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
- 7.1.2. Market Attractiveness Index, By Mode of Prescription
- 7.2. Prescription-Based*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Over-the-Counter
- 8. By Distribution Channel
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Retail Pharmacies*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Hospital Pharmacies
- 8.4. Clinics
- 8.5. Online Pharmacies
- 8.6. Others
- 9. Regional Market Analysis and Growth Opportunities
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.7.1. U.S.
- 9.2.7.2. Canada
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.7.1. Germany
- 9.3.7.2. U.K.
- 9.3.7.3. France
- 9.3.7.4. Spain
- 9.3.7.5. Italy
- 9.3.7.6. Rest of Europe
- 9.4. Latin America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.7.1. Mexico
- 9.4.7.2. Brazil
- 9.4.7.3. Argentina
- 9.4.7.4. Rest of Latin America
- 9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.7.1. China
- 9.5.7.2. India
- 9.5.7.3. Japan
- 9.5.7.4. South Korea
- 9.5.7.5. Rest of Asia-Pacific
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
- 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10. Competitive Landscape and Market Positioning
- 10.1. Competitive Overview and Key Market Players
- 10.2. Market Share Analysis and Positioning Matrix
- 10.3. Strategic Partnerships, Mergers & Acquisitions
- 10.4. Key Developments in Product Portfolios and Innovations
- 10.5. Company Benchmarking
- 11. Company Profiles
- 11.1. Bayer AG*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.2.1. Product Description
- 11.1.2.2. Product Key Performance Indicators (KPIs)
- 11.1.2.3. Historic and Forecasted Product Sales
- 11.1.2.4. Product Sales Volume
- 11.1.3. Financial Overview
- 11.1.3.1. Company Revenue’s
- 11.1.3.2. Geographical Revenue Shares
- 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
- 11.1.4.1. Mergers & Acquisitions
- 11.1.4.2. Key Product Development Activities
- 11.1.4.3. Regulatory Approvals, etc.
- 11.1.5. SWOT Analysis
- 11.2. Haleon Group of Companies
- 11.3. Kenvue
- 11.4. Teva Pharmaceuticals USA, Inc
- 11.5. Viatris Inc
- 11.6. Pfizer Inc
- 11.7. Purdue Pharmaceuticals L.P
- 11.8. Abbott
- 11.9. Collegium Pharmaceutical, Inc
- 11.10. Sun Pharmaceutical Industries Ltd (LIST NOT EXHAUSTIVE)
- 12. Assumption and Research Methodology
- 12.1. Data Collection Methods
- 12.2. Data Triangulation
- 12.3. Forecasting Techniques
- 12.4. Data Verification and Validation
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
